We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
43 hedge funds and large institutions have $31.7M invested in Crescent Biopharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 18 reducing their positions, and 7 closing their positions.
New
Increased
Maintained
Reduced
Closed
4,300% more call options, than puts
Call options by funds: $132K | Put options by funds: $3K
0.05% less ownership
Funds ownership: 0.57% → 0.52% (-0.05%)
9% less funds holding
Funds holding: 47 → 43 (-4)
26% less capital invested
Capital invested by funds: $42.7M → $31.7M (-$11M)
56% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 18
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Holders
43
Holders Change
-4
Holders Change %
-8.51%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
8
Reduced
18
Closed
7
Calls
$132K
Puts
$3K
Net Calls
+$129K
Net Calls Change
+$247K
Top Buyers
Top Sellers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$497K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$344K |
| 3 |
Millennium Management
New York
|
-$337K |
| 4 |
Two Sigma Advisers
New York
|
-$312K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$255K |
